Actively Recruiting
Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region
Led by University of Erlangen-Nürnberg Medical School · Updated on 2026-03-13
100
Participants Needed
1
Research Sites
678 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective registry study based on a standard therapy concept for postoperative simultaneous radiochemotherapy established in Erlangen and elsewhere. The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated. Patients with locally advanced high-grade salivary gland carcinoma after oncological resection are admitted.
CONDITIONS
Official Title
Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Salivary gland carcinomas of the major and minor salivary glands of the head and neck region
- High-grade histology
- Successful oncological resection with curative intent
- pT3-4 or pN1-3 or Pn1 (perineural sheath infiltration) or pT1-2 with scarce or positive resection margin
- cM0 (no distant metastases)
- Indication for postoperative combined radiochemotherapy following guidelines
- Percutaneous radiotherapy up to 64-72 Gy depending on resection status
- Chemotherapy regimens including paclitaxel with cisplatin or carboplatin in specified dosing schedules
- Patient age 18 years or older
- WHO performance score of 0 or 1
- Signed informed consent form
You will not qualify if you...
- Presence of distant metastases
- Other cancer diagnosed within the last 5 years, except adequately treated skin cancer (non-melanoma), lentigo maligno, or carcinoma in situ without active disease
- Previous chemotherapy or radiotherapy for salivary gland carcinoma
- Previous radiotherapy in the head and neck region
- Uncontrolled medical conditions contraindicating combined chemotherapy (e.g., recent heart attack, heart failure, severe heart disease, resistant infection, immunodeficiency)
- Pregnancy or breastfeeding
- Fertile patients unable to ensure effective contraception during and for six months after therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Erlangen, Universitätsklinikum Strahlenklinik
Erlangen, Germany, 91054
Actively Recruiting
Research Team
M
Marlen Haderlein, PD Dr.
CONTACT
S
Studiensekretariat
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here